Abstract:<h3>Importance</h3><p>Coronavirus disease 2019 (COVID-19) continues to cause considerable morbidity and mortality worldwide. Case reports of hospitalized patients suggest that COVID-19 prominently affects the cardiovascular system, but the overall impact remains unknown.</p><h3>Objective</h3><p>To evaluate the presence of myocardial injury in unselected patients recently recovered from COVID-19 illness.</p><h3>Design, Setting, and Participants</h3><p>In this prospective observational cohort study, 100 patients recently recovered from COVID-19 illness were identified from the University Hospital Frankfurt COVID-19 Registry between April and June 2020.</p><h3>Exposure</h3><p>Recent recovery from severe acute respiratory syndrome coronavirus 2 infection, as determined by reverse transcription–polymerase chain reaction on swab test of the upper respiratory tract.</p><h3>Main Outcomes and Measures</h3><p>Demographic characteristics, cardiac blood markers, and cardiovascular magnetic resonance (CMR) imaging were obtained. Comparisons were made with age-matched and sex-matched control groups of healthy volunteers (n = 50) and risk factor–matched patients (n = 57).</p><h3>Results</h3><p>Of the 100 included patients, 53 (53%) were male, and the mean (SD) age was 49 (14) years. The median (IQR) time interval between COVID-19 diagnosis and CMR was 71 (64-92) days. Of the 100 patients recently recovered from COVID-19, 67 (67%) recovered at home, while 33 (33%) required hospitalization. At the time of CMR, high-sensitivity troponin T (hsTnT) was detectable (greater than 3 pg/mL) in 71 patients recently recovered from COVID-19 (71%) and significantly elevated (greater than 13.9 pg/mL) in 5 patients (5%). Compared with healthy controls and risk factor–matched controls, patients recently recovered from COVID-19 had lower left ventricular ejection fraction, higher left ventricle volumes, and raised native T1 and T2. A total of 78 patients recently recovered from COVID-19 (78%) had abnormal CMR findings, including raised myocardial native T1 (n = 73), raised myocardial native T2 (n = 60), myocardial late gadolinium enhancement (n = 32), or pericardial enhancement (n = 22). There was a small but significant difference between patients who recovered at home vs in the hospital for native T1 mapping (median [IQR], 1119 [1092-1150] ms vs 1141 [1121-1175] ms;<i>P</i> = .008) and hsTnT (4.2 [3.0-5.9] pg/dL vs 6.3 [3.4-7.9] pg/dL;<i>P</i> = .002) but not for native T2 mapping. None of these measures were correlated with time from COVID-19 diagnosis (native T1:<i>r</i> = 0.07;<i>P</i> = .47; native T2:<i>r</i> = 0.14;<i>P</i> = .15; hsTnT:<i>r</i> = −0.07;<i>P</i> = .50). High-sensitivity troponin T was significantly correlated with native T1 mapping (<i>r</i> = 0.33;<i>P</i> < .001) and native T2 mapping (<i>r</i> = 0.18;<i>P</i> = .01). Endomyocardial biopsy in patients with severe findings revealed active lymphocytic inflammation. Native T1 and T2 were the measures with the best discriminatory ability to detect COVID-19–related myocardial pathology.</p><h3>Conclusions and Relevance</h3><p>In this study of a cohort of German patients recently recovered from COVID-19 infection, CMR revealed cardiac involvement in 78 patients (78%) and ongoing myocardial inflammation in 60 patients (60%), independent of preexisting conditions, severity and overall course of the acute illness, and time from the original diagnosis. These findings indicate the need for ongoing investigation of the long-term cardiovascular consequences of COVID-19.</p>

Trajectory of cardiac troponin T following moderate-to-severe COVID-19 and the association with cardiac abnormalities

High-Sensitivity Cardiac Troponin T for the Detection of Myocardial Injury and Risk Stratification in COVID-19

Elevated High Sensitivity Cardiac Troponin T is Nonlinearly Associated with Poor Prognosis in Aging COVID-19 Patients: A Retrospective Study.

Changes in Subclinical Cardiac Abnormalities 1 Year after Recovering from COVID-19 in Patients Without Clinical Cardiac Findings

Elevated Cardiac Troponin I as a Mortality Predictor in Hospitalised COVID-19 Patients

Early Cardiac Involvement in Patients with Acute COVID-19 Infection Identified by Multiparametric Cardiovascular Magnetic Resonance Imaging

Serial high sensitivity troponin sampling in patients with SARS-CoV-2 infection

Role of a lower cutoff of high sensitivity troponin I in identification of early cardiac damage in non-severe patients with COVID-19

Incidence, Prognosis, and Clinical Outcomes—Results from a Multi-Center International Prospective Registry (HOPE-2)

A-019 Unexpectedly High Cardiac Troponin Values in Healthy Athletes after SARS-CoV-2 Infection

False-positive cardiac troponin I values in healthy athletes post COVID-19 Infection: concerning insights from a prospective cohort study

Evaluation of cardiac injury with biomarkers and echocardiography after COVID-19 infection

Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease

Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients

The Prognostic Value of Cardiac Biomarkers and Echocardiography in Critical COVID-19

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)

The Peak Levels of Highly Sensitive Troponin I Predicts In-Hospital Mortality in COVID-19 Patients with Cardiac Injury: a Retrospective Study.

Cardiac Troponin I Associated with Poor Prognosis and Death Risk in 726 Severe and Critical COVID-19 Patients: A Retrospective Cohort Study

Cardiac Injury Biomarkers and the Risk of Death in Patients with COVID-19: A Systematic Review and Meta-Analysis

The differences in troponin values among gender in COVID-19 patients

Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study